Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks

被引:93
|
作者
Buscemi, G
Perego, P
Carenini, N
Nakanishi, M
Chessa, L
Chen, JJ
Khanna, K
Delia, D
机构
[1] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy
[2] Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[3] Osped S Andrea, I-00189 Rome, Italy
[4] Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA
[5] Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA
[6] Mayo Clin & Mayo Fdn, Dept Adolescent Med, Rochester, MN 55905 USA
[7] Queensland Inst Med Res, Mol & Cellular Biol Div, Brisbane, Qld 4006, Australia
关键词
ATM; Chk2; DNA double-strand breaks; checkpoints;
D O I
10.1038/sj.onc.1207986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The diverse checkpoint responses to DNA damage may reflect differential sensitivities by molecular components of the damage-signalling network to the type and amount of lesions. Here, we determined the kinetics of activation of the checkpoint kinases ATM and Chk2 ( the latter substrate of ATM) in relation to the initial yield of genomic DNA single-strand (SSBs) and double-strand breaks (DSBs). We show that doses of gamma-radiation (IR) as low as 0.25 Gy, which generate vast numbers of SSBs but only a few DSBs per cell (<8), promptly activate ATM kinase and induce the phosphorylation of the ATM substrates p53 - Ser15, Nbs1 - Ser343 and Chk2 - Thr68. The full activation of Chk2 kinase, however, is triggered by treatments inflicting >19 DSBs per cell (e.g. 1 Gy), which cause Chk2 autophosphorylation on Thr387, Chk2-dependent accumulation of p21(waf1) and checkpoint arrest in the S phase. Our results indicate that, in contrast to ATM, Chk2 activity is triggered by a greater number of DSBs, implying that, below a certain threshold level of lesions (<19 DSBs), DNA repair can occur through ATM, without enforcing Chk2-dependent checkpoints.
引用
收藏
页码:7691 / 7700
页数:10
相关论文
共 50 条
  • [1] Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks
    Giacomo Buscemi
    Paola Perego
    Nives Carenini
    Makoto Nakanishi
    Luciana Chessa
    Junjie Chen
    KumKum Khanna
    Domenico Delia
    Oncogene, 2004, 23 : 7691 - 7700
  • [2] Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks
    Chen, JJ
    Ward, IM
    Wu, XL
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 404A - 404A
  • [3] Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks.
    Ward, IM
    Wu, XL
    Chen, JJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) : 47755 - 47758
  • [4] Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR
    Dellaire, Graham
    Ching, Reagan W.
    Ahmed, Kashif
    Jalali, Farid
    Tse, Kenneth C. K.
    Bristow, Robert G.
    Bazett-Jones, David P.
    JOURNAL OF CELL BIOLOGY, 2006, 175 (01): : 55 - 66
  • [5] Rapid activation of ATM on DNA flanking double-strand breaks
    You, Zhongsheng
    Bailis, Julie M.
    Johnson, Sam A.
    Dilworth, Stephen M.
    Hunter, Tony
    NATURE CELL BIOLOGY, 2007, 9 (11) : 311 - U193
  • [6] Rapid activation of ATM on DNA flanking double-strand breaks
    Zhongsheng You
    Julie M. Bailis
    Sam A. Johnson
    Stephen M. Dilworth
    Tony Hunter
    Nature Cell Biology, 2007, 9 : 1311 - 1318
  • [7] ATM-dependent CHK2 activation induced by anticancer agent, irofulven
    Wang, J
    Wiltshire, T
    Wang, YT
    Mikell, C
    Burks, J
    Cunningham, C
    Van Laar, ES
    Waters, SJ
    Reed, E
    Wang, WX
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) : 39584 - 39592
  • [8] Chk1 and Chk2 kinases in checkpoint control and cancer
    Bartek, J
    Lukas, J
    CANCER CELL, 2003, 3 (05) : 421 - 429
  • [9] Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
    Reinhardt, H. Christian
    Yaffe, Michael B.
    CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) : 245 - 255
  • [10] ATM-dependent CHK2 activation induced by the anticancer agent, irofulven.
    Wang, WX
    Wang, J
    Van Laar, ES
    Waters, SJ
    Yu, JJ
    Reed, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6083S - 6084S